Pancreatic Carcinoma — Trials

Pancreatic Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 488
Recruiting: 282
Ph III recruiting: 29
Growth YoY: +31.5%
Industry share: 36%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (201)

clinicaltrialsPublishedShowing 51–100 of 226 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07157033	A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.(XER-001)	recruiting	Phase 1 / Phase 2	36	Xerient PharmaINDUSTRY	1	Aug 17, 2026	clinicaltrials
NCT05985655	Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE)	recruiting	Phase 1 / Phase 2	230	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.